Hepatitis C comorbidities affecting the course and response to therapy

El-Zayadi, Abdel-Rahman; Burczynski, Frank J.
October 2009
World Journal of Gastroenterology;10/28/2009, Vol. 15 Issue 40, p4993
Academic Journal
Several studies have demonstrated that the outcome of chronic hepatitis C (CHC) infection is profoundly influenced by a variety of comorbidities. Many of these comorbidities have a significant influence on the response to antiviral therapy. These comorbidities negatively affect the course and outcome of liver disease, often reducing the chance of achieving a sustained virological response with PEGylated interferon and ribavirin treatments. Comorbidities affecting response to antiviral therapy reduce compliance and adherence to inadequate doses of therapy. The most important comorbidities affecting the course of CHC include hepatitis B virus coinfection, metabolic syndrome, and intestinal bacterial overgrowth. Comorbidities affecting the course and response to therapy include schistosomiasis, iron overload, alcohol abuse, and excessive smoking. Comorbidities affecting response to antiviral therapy include depression, anemia, cardiovascular disease, and renal failure.


Related Articles

  • The Impact of Antiviral Therapy and the Influence of Metabolic Cofactors on the Outcome of Chronic HCV Infection. Persico, Marcello; Bruno, Savino; Costantino, Andrea; Mazza, Marta; Almasio, Piero Luigi // International Journal of Hepatology;2011, p1 

    Natural history of HCV related chronic hepatitis is influenced and modified by many factors: virus features, coinfections and host characteristics. In particular, a peculiar genetic background of the host by conditioning the occurrence of intracellular metabolic derangements (i.e., insulin...

  • Changing Outcomes for Patients with Chronic Hepatitis C.  // Infectious Disease Alert;Mar2013 Clinical Briefs in Primary Care, p6 

    The article discusses research by A. J. van der Meer and colleagues, published in a 2012 issue of the "Journal of the American Medical Association" on the outcomes of chronic hepatitis C (HEPc) patients with long-term follow-up and biopsy-proven fibrosis.

  • All-Cause Mortality and Liver-Related Outcomes Following Successful Antiviral Treatment for Chronic Hepatitis C. Dieperink, Eric; Pocha, Christine; Thuras, Paul; Knott, Astrid; Colton, Samuel; Ho, Samuel // Digestive Diseases & Sciences;Apr2014, Vol. 59 Issue 4, p872 

    Background: Antiviral therapy for the hepatitis C virus (HCV) reduces all-cause and liver-related morbidity and mortality. Few studies are available from populations with multiple medical and psychiatric comorbidities where the impact of successful antiviral therapy might be limited. Aim: The...

  • IFNL4-ΔG Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin. Meissner, Eric G.; Bon, Dimitra; Prokunina-Olsson, Ludmila; Tang, Wei; Masur, Henry; O'Brien, Thomas R.; Herrmann, Eva; Kottilil, Shyamasundaran; Osinusi, Anuoluwapo // Journal of Infectious Diseases;Jun2014, Vol. 209 Issue 11, p1700 

    Response to pegylated interferon-alpha and ribavirin (IFN-α/RBV) treatment for chronic hepatitis C virus (HCV) infection is influenced by host genetic factors, but their role for IFN-α–free, direct-acting antiviral (DAA) regimens is unclear. An exonic deletion allele (IFNL4-ΔG)...

  • Antivirals for hepatitis C improve kidney and cardiovascular disease in diabetic patients.  // British Journal of Hospital Medicine (17508460);Jan2014, Vol. 75 Issue 1, p10 

    The article provides an overview of the study "Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients" published in the October 12, 2013 issue of the periodical "Hepatology."

  • Occult HCV or delayed viral clearance from lymphocytes of Chronic HCV genotype 3 patients after interferon therapy.  // Genetic Vaccines & Therapy;2011, Vol. 9 Issue 1, p14 

    The article presents a research which aimed to determine the prevalence of occult Hepatitis C virus (HCV) in peripheral blood lymphocytes of HCV genotype 3-infected patients treated with antiviral therapy, and to study therapy outcomes in the presence or absence of peripheral blood mononuclear...

  • Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Arcaini, L.; Vallisa, D.; Rattotti, S.; Ferretti, V. V.; Ferreri, A. J. M.; Bernuzzi, P.; Merli, M.; Varettoni, M.; Chiappella, A.; Ambrosetti, A.; Tucci, A.; Rusconi, C.; Visco, C.; Spina, M.; Cabras, G.; Luminari, S.; Tucci, M.; Musto, P.; Ladetto, M.; Merli, F. // Annals of Oncology;Jul2014, Vol. 25 Issue 7, p1404 

    Present study demonstrates that antiviral treatment plays an anti-lymphoma activity in HCV-associated indolent B-cell lymphomas and that the use of antiviral treatment at any time during the life of these patients is clearly associated with improved outcome.Despite the limitations related to...

  • Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran. Namazee, Najmeh; Sali, Shahnaz; Asadi, Sorour; Shafiei, Mostafa; Behnava, Bita; Alavian, Seyed Moayed // Hepatitis Monthly;2012, Vol. 12 Issue 9, p1 

    Background: Despite significant advances in the treatment of chronic hepatitis C in the past decades, factors which can affect response rates to combination therapy; peginterferon and ribavirin, are still under study and reaching sustained virological response (SVR) is affected by several...

  • New Hope for Hepatitis C Patients.  // Hospital Medicine Alert;Sep2013 Clinical Briefs in Primary Care, p18 

    The article discusses research on the effect of sofosbuvir in patients with hepatitis C, with reference to a study by I. M. Jacobson et al., published in "The New England Journal of Medicine" in 2013.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics